🇺🇸 FDA
Patent

US 8425907

Methods for treating pruritus by administering an antibody that specifically binds human PAR2

granted A61KA61K2039/505A61K39/3955

Quick answer

US patent 8425907 (Methods for treating pruritus by administering an antibody that specifically binds human PAR2) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Apr 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2039/505, A61K39/3955, A61K45/06, A61P